A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients . (2016). Clinics, 71(10), 586-592. https://doi.org/10.6061/clinics/2016(10)06